Abstract:
Objective This study aimed to observe the clinical efficacy of implanting radioactive 125I seeds to treat non-small cell lung cancer (NSCLC) on the basis of the recent changes in serum tumor markers (including CEA, CA125, SCC-Ag, and CYFRA21-1).
Methods We selected 72 patients who were pathologically confirmed with NSCLC and received CT-guided percutaneous implantation of radioactive 125I seeds from January 2009 to June 2012. The concentration of the serum tumor markers was detected 3 d before implantation and 1, 2, 3, and 6 months after implantation.
Results All of the operations were successfully completed. One month after implantation, a significant change was observed in the concentration of serum tumor markers (CEA, CA125, SCC-Ag, and CYFRA21-1) compared with their preoperative levels (P < 0.01). No significant difference was observed between the different time points after implantation.
Conclusion The treatment of NSCLC by implanting radioactive 125I seeds can effectively reduce the level of tumor markers. A significant difference was observed in the level of tumor markers between patients with different efficacy classifications.